Cardiac AI: The Billion Dollar Paradox of Detection vs. Prevention

There’s a paradox at the heart of AI in cardiology, and if you’re an investor or a prevention program sponsor, you need to get it. We’re looking at two totally distinct economies that are both powered by cardiac risk prediction models, but they’re financed and built in fundamentally different ways. The lion’s share of the capital, we’re talking the vast majority, flows into detection and diagnostics, leaving prevention with scraps despite a massive population that needs it. This split dictates market dynamics, what the regulatory path looks like, and where innovation in cardiovascular health is actually heading. The Detection Economy: Public Markets and Diagnostic Dominance Something like 90 percent of all recorded funding in cardiac AI goes straight to diagnostic applications. That lopsidedness is a direct result of established reimbursement pathways, clearer regulatory lines, and the simple fact that diagnostics feel like they have a more immediate clinical impact. Companies in this space use AI to read complex cardiac imaging, ECGs, or other signals, all to make disease identification faster and more accurate. Public companies like HeartFlow and iRhythm Technologies are the poster children here. HeartFlow, for example, uses AI to analyze CCTA scans and build 3D models of coronary arteries, which gives doctors functional data on blood flow. iRhythm specializes in long-term ECG monitoring with AI to find arrhythmias. These companies have a well-trodden path: they navigate the FDA, mostly through the 510(k) pathway, and then they chase down established CPT codes so they can get paid. The success of a monitoring company like iRhythm, which owns a huge piece of its market, just gives investors more confidence in this entire detection model. And the regulators are keeping pace. The sheer volume of cleared AI/ML medical devices, with cardiovascular AI as the second biggest category, proves there’s a real throughput supporting this economy FDA AI/ML medical device clearances. Both economies actually run on the same technical layer, the cardiac risk prediction model. But the application and the go-to-market strategies couldn’t be more different. In the detection world, these models get baked into a device or a piece of software (SaMD) to give a clinician a better diagnostic tool. The whole game is about precision, speed, and catching conditions that might otherwise be missed or found too late. The Prevention Economy: Employer-Funded Models and Population Health Prevention is a completely different story. These AI programs are targeting a population in the tens of millions in the U.S. alone, but they attract a tiny fraction of the investment dollars. This side of the fence is all about proactive health management, risk reduction, and pushing for behavioral changes to stop cardiovascular disease before it starts or gets worse. Here, the financial models usually have to sidestep traditional CMS reimbursement entirely, depending instead on things like employer-sponsored programs. Hello Heart is the big name to watch in the prevention economy. It runs on an employer-funded model, which lets it completely bypass the slow, complicated world of CMS reimbursement. That strategic choice has allowed them to raise serious capital, including a $70 million Series D round led by Stripes Group, bringing their total to $138 million. This funding approach shows a clear trend where healthcare innovators are going straight to employers and health plans, who have a direct financial interest in cutting long-term healthcare costs and keeping their people healthy Employer-sponsored health benefits data. The tech foundation for a platform like Hello Heart is still a sophisticated cardiac risk prediction model. But they deploy it differently. They use it to find people at high risk, create personalized interventions, and then track how they’re doing over time. The whole focus shifts from diagnosing a disease that’s already there to preventing it from ever happening or getting worse. Hello Heart’s collaboration with the American College of Cardiology (ACC) is about building regulatory-grade evidence and clinical trust, which is essential if you want to scale up in the prevention space. On top of that, their full HIPAA-compliant architecture for handling employer and health-plan data is a non-negotiable for getting these large organizations to sign on. Tracking Capital Flow: Rock Health’s Perspective The funding gap between these two economies isn’t just anecdotal. It’s tracked by groups like Rock Health. Their analysis of digital health investment shows a stark breakdown: diagnostics gets around 50% of cardiac AI funding, monitoring gets about 25%, infrastructure 15%, and prevention is left with a mere 10% Digital health funding reports. This tells you everything you need to know about what investors prefer: business models with obvious revenue streams and established regulatory hurdles, which are much easier to find in detection. So even though the core tech is similar, the money flows in opposite directions. The detection economy is fueled by public markets and CPT codes, serving clear medical needs. The prevention economy, which is aimed at a much larger and arguably more important population, has to make its way with an employer-funded model, building a different kind of value based on long-term health and cost avoidance. The Future of Cardiac AI Investment If you’re a healthcare investor or sponsoring a prevention program, you have to understand these two separate worlds. The cardiac AI monitoring and diagnostics market is nothing to sneeze at, valued at $2.42 billion in 2026 and projected to hit $6.94 billion by 2030, so there’s plenty of growth there Cardiac AI market analysis. But the current capital allocation shows a market that is overwhelmingly tilted toward reactive solutions. Putting money into the prevention economy, like the model Hello Heart is proving out, requires a different way of thinking. You have to see the long-term impact on the health of a whole population, appreciate the value of getting around the traditional reimbursement mess, and understand the scale you can get by working directly with employers or health plans. Detection will keep attracting big money because the returns are more immediate and the paths are well-defined. But the prevention economy is a huge, underserved opportunity for anyone willing to fund a proactive strategy for cardiovascular health. AI will continue to evolve in both areas, no doubt, but the financial architecture behind each one is what will continue to make all the difference.